A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer

Trial Profile

A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Telatinib (Primary) ; Capecitabine; Cisplatin
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Sponsors ACT Biotech
  • Most Recent Events

    • 31 Mar 2015 Status changed from completed to discontinued as per M.D. Anderson Cancer Center record.
    • 07 Feb 2012 Actual end date (Jan 2012) added as reported by ClinicalTrials.gov.
    • 07 Feb 2012 Actual patient number is 48 according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top